Bank of America Has Lowered Expectations for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its target price lowered by equities research analysts at Bank of America from $153.00 to $150.00 in a report issued on Friday, Marketbeat reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Bank of America‘s price target points to a potential upside of 7.91% from the stock’s previous close.

A number of other analysts have also commented on the company. Sanford C. Bernstein decreased their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating for the company in a report on Tuesday, November 26th. UBS Group raised their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Citigroup upped their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Wells Fargo & Company dropped their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. Finally, TD Cowen upped their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $143.62.

Agilent Technologies Price Performance

Shares of NYSE A opened at $139.00 on Friday. The firm has a market capitalization of $39.94 billion, a P/E ratio of 31.45, a P/E/G ratio of 4.48 and a beta of 1.07. The firm’s 50-day moving average price is $136.75 and its 200-day moving average price is $136.44. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. Agilent Technologies has a 1-year low of $124.16 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 earnings per share. Equities research analysts anticipate that Agilent Technologies will post 5.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Crewe Advisors LLC grew its position in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Livelsberger Financial Advisory purchased a new position in Agilent Technologies during the third quarter worth about $28,000. Ridgewood Investments LLC purchased a new position in Agilent Technologies during the second quarter worth about $29,000. Ashton Thomas Securities LLC bought a new position in Agilent Technologies in the 3rd quarter worth about $31,000. Finally, Fortitude Family Office LLC raised its holdings in shares of Agilent Technologies by 68.3% in the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 95 shares in the last quarter. Institutional investors own 87.42% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.